No abstract available.
Acellular Dermis* ; Animals ; Dogs* ; Transplants*

No abstract available.
Animals ; Bone Regeneration* ; Dental Implants* ; Dogs*

No abstract available.
Carbapenems* ; Korea*

No abstract available.
Carbapenems* ; Korea*

Fibrolamellar hepatocellular carcinoma (FLHCC) is a rare liver cancer affecting adolescents and young adults without any pre existing liver disease. Hyperammonemic encephalopathy (HAE) is a serious paraneoplastic syndrome, and several cases of HAE have been reported in patients with FLHCC. This condition is rare; hence, there are currently no management guidelines for cancer-related HAE. Herein, we report a case of an 18-year-old man with advanced FLHCC who developed HAE during the first course of chemotherapy consisting of cisplatin, doxorubicin, 5-fluorouracil, and interferon-α. He was successfully treated with continuous venovenous hemofiltration, sodium benzoate, sodium phenylbutyrate, and amino acid supplementation for HAE. After the second course of chemotherapy, he underwent surgery, and thereafter, his ammonia levels were normal without any ammonia scavenger therapy. Treatments for HAE described here will be helpful for this rare, but serious metabolic complication of FLHCC and could partially applied to HAE related to any malignancies.

Primary pulmonary amyloidosis is a rare condition that can be classified into the tracheobronchial, diffuse alveolar septal, and nodular parenchymal type. Tracheobronchial amyloidosis is characterized by deposition of fib rilar proteins in the tracheobronchial tree, and it can be subdivided into diffuse and focal varieties. In this report, a case of diffuse tracheobronchial amyloidosis confirmed by flexible fiberoptic bronchoscopic biopsy is presented. The patient was a 43-year old male with a chief complaint of cough and sputum for 20 days and dyspnea for one day. The chest CT scan showed diffusely thickened walls of both the main and lobar bronchi with calcification. The bronchoscopic findings showed nodular lesions of the trachea, a diffuse bronchial stenosis of both the main bronchi and a pinpoint narrowing of the left upper and right middle lobar bronchus. The biopsy showed submucosal deposits of homogenous eosinophilic amyloid materials and an apple-green birefringence under polarizing microscopy following the Congo-red stain.
Adult ; Amyloid ; Amyloidosis* ; Biopsy ; Birefringence ; Bronchi ; Bronchoscopy ; Constriction, Pathologic ; Cough ; Dyspnea ; Eosinophils ; Humans ; Male ; Microscopy ; Sputum ; Tomography, X-Ray Computed ; Trachea

OBJECTIVE:This study was performed to compare the in vitro antimicrobial activities of prepenem (PRPM) with those of imipenem (IMPM) and meropenem (MRPM) against several clinical isolates of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Streptococcus pneumoniae. METHODS: We tested the in vitro antimicrobial activities of PRPM, IMPM, and MRPM against total 300 clinical isolates of E. coli, K. pneumoniae, and P. aeruginosa and 134 chinical isolated of S. pneumoniae (41 penicillin-susceptible, 93 penicillin-resistant strains) collected in 5 different university hospitals (March to June, 2002). According to NCCLS guidelines, MICs of PRPM, IMPM, MRPM, and/or ceftazidime were determined. RESULTS: MIC90s of E. coli to IMPM, PRPM, and MRPM were 1, 1, and 0.125 microgram/mL, respectively. Those of K. pneumoniae were 1, 0.5, and 0.125 microgram/mL, respectively. In case of P. aeruginosa, MIC90s to IMPM, PRPM, MRPM, and ceftazidime were 16, 32, 8, and 64 microgram/mL, respectively. In penicillin-susceptible S. pneumoniae, MIC90s to IMPM, PRPM, MRPM were 0.25, 0.25, 0.5 microgram/mL, while those of penicillin-nonsusceptible strains were 1, 1, and 2 microgram/mL, respectively. IMPM and PRPM showed similar pattern of distribution of MIC to various bacterial species. CONCLUSION: E. coli, K. pneumoniae, and S. pneumonia were susceptible to PRPM, which had a pattern similar to IMPM. The antimicrobial activity of PRPM to P. aeruginosa was also comparable to that of IMPM. PRPM could be potentially useful drugs for treatment of infections caused by E. coli, K. pneumoniae, P. aeruginosa and S. pneumoniae.
Carbapenems* ; Ceftazidime ; Escherichia coli ; Hospitals, University ; Imipenem ; Klebsiella pneumoniae ; Korea* ; Pneumonia ; Pseudomonas aeruginosa ; Streptococcus pneumoniae

OBJECTIVE:This study was performed to compare the in vitro antimicrobial activities of prepenem (PRPM) with those of imipenem (IMPM) and meropenem (MRPM) against several clinical isolates of Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Streptococcus pneumoniae. METHODS: We tested the in vitro antimicrobial activities of PRPM, IMPM, and MRPM against total 300 clinical isolates of E. coli, K. pneumoniae, and P. aeruginosa and 134 chinical isolated of S. pneumoniae (41 penicillin-susceptible, 93 penicillin-resistant strains) collected in 5 different university hospitals (March to June, 2002). According to NCCLS guidelines, MICs of PRPM, IMPM, MRPM, and/or ceftazidime were determined. RESULTS: MIC90s of E. coli to IMPM, PRPM, and MRPM were 1, 1, and 0.125 microgram/mL, respectively. Those of K. pneumoniae were 1, 0.5, and 0.125 microgram/mL, respectively. In case of P. aeruginosa, MIC90s to IMPM, PRPM, MRPM, and ceftazidime were 16, 32, 8, and 64 microgram/mL, respectively. In penicillin-susceptible S. pneumoniae, MIC90s to IMPM, PRPM, MRPM were 0.25, 0.25, 0.5 microgram/mL, while those of penicillin-nonsusceptible strains were 1, 1, and 2 microgram/mL, respectively. IMPM and PRPM showed similar pattern of distribution of MIC to various bacterial species. CONCLUSION: E. coli, K. pneumoniae, and S. pneumonia were susceptible to PRPM, which had a pattern similar to IMPM. The antimicrobial activity of PRPM to P. aeruginosa was also comparable to that of IMPM. PRPM could be potentially useful drugs for treatment of infections caused by E. coli, K. pneumoniae, P. aeruginosa and S. pneumoniae.
Carbapenems* ; Ceftazidime ; Escherichia coli ; Hospitals, University ; Imipenem ; Klebsiella pneumoniae ; Korea* ; Pneumonia ; Pseudomonas aeruginosa ; Streptococcus pneumoniae

BACKGROUND: Chronic obstructive pulmonary disease (COPD) is a major cause of chronic morbidity and mortality throughout the world and is the only major disease that is continuing to increase in both prevalence and mortality. The second Korean National Health and Nutrition Survey revealed that the prevalence of COPD in Korean subjects aged > or =45 years was 17.2% in 2001. Further surveys on the prevalence of COPD were not available until 2007. Here, we report the prevalence of spirometrically detected COPD in Korea, using data from the fourth Korean National Health and Nutrition Survey (KNHANES IV) which was conducted in 2007~2009. METHODS: Based on the Korean Statistical Office census that used nationwide stratified random sampling, 10,523 subjects aged > or =40 years underwent spirometry. Place of residence, levels of education, income, and smoking status, as well as other results from a COPD survey questionnaire were also assessed. RESULTS: The prevalence of COPD (defined as forced expiratory volume in 1 sec/forced vital capacity <0.7 in subjects aged > or =40 years) was 12.9% (men, 18.7%; women, 7.5%). In total, 96.5% of patients with COPD had mild-to-moderate disease; only 2.5% had been diagnosed by physicians, and only 1.7% had been treated. The independent risk factors for COPD were smoking, advanced age, and male gender. CONCLUSION: The prevalence of COPD was 12.9% in the KNHANES IV data. Most patients with COPD were undiagnosed and untreated. Based on these results, a strategy for early COPD intervention is warranted in high risk subjects.
Aged ; Censuses ; Female ; Forced Expiratory Volume ; Humans ; Hypogonadism ; Korea ; Male ; Mitochondrial Diseases ; Nutrition Surveys ; Ophthalmoplegia ; Prevalence ; Pulmonary Disease, Chronic Obstructive ; Surveys and Questionnaires ; Risk Factors ; Smoke ; Smoking ; Spirometry ; Vital Capacity